TyPed study: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal
Open Access
- 24 February 2021
- journal article
- research article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 51, 102865
- https://doi.org/10.1016/j.msard.2021.102865
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitionsMultiple Sclerosis Journal, 2013
- Capture-Recapture as a Potentially Useful Procedure for Assessing Prevalence of Multiple Sclerosis: Methodologic Exercise Using Portuguese DataNeuroepidemiology, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Safety and efficacy of natalizumab in children with multiple sclerosisNeurology, 2010
- Natalizumab in pediatric multiple sclerosis patientsTherapeutic Advances in Neurological Disorders, 2010
- Pediatric multiple sclerosisAnnals of Indian Academy of Neurology, 2009
- Consensus definitions proposed for pediatric multiple sclerosis and related disordersNeurology, 2007
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisThe New England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2005